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Abstract
Defining the contribution of acetylcholine to specific behaviors has been challenging, mainly because of the difficulty in
generating suitable animal models of cholinergic dysfunction. We have recently shown that, by targeting the vesicular
acetylcholine transporter (VAChT) gene, it is possible to generate genetically modified mice with cholinergic deficiency.
Here we describe novel VAChT mutant lines. VAChT gene is embedded within the first intron of the choline
acetyltransferase (ChAT) gene, which provides a unique arrangement and regulation for these two genes. We generated a
VAChT allele that is flanked by loxP sequences and carries the resistance cassette placed in a ChAT intronic region (FloxNeo
allele). We show that mice with the FloxNeo allele exhibit differential VAChT expression in distinct neuronal populations.
These mice show relatively intact VAChT expression in somatomotor cholinergic neurons, but pronounced decrease in other
cholinergic neurons in the brain. VAChT mutant mice present preserved neuromuscular function, but altered brain
cholinergic function and are hyperactive. Genetic removal of the resistance cassette rescues VAChT expression and the
hyperactivity phenotype. These results suggest that release of ACh in the brain is normally required to ‘‘turn down’’
neuronal circuits controlling locomotion.
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Introduction
Acetylcholine (ACh) is the major peripheral neurotransmitter
controlling the parasympathetic and the sympathetic autonomic
nervous system as well as the somatic motor system. Moreover, the
cholinergic system is thought to play key roles in many functions in
the CNS, including the control of locomotor activity, emotional
behavior, and higher cognitive processes such as learning and
memory [1–3]. Changes in cholinergic neurotransmission are
associated with a variety of important neurological disorders
including Alzheimer’s disease, schizophrenia, Parkinson’s disease,
epilepsy and attention-deficit hyperactivity disorder [4].
ACh changes cellular activity of target cells through metabo-
tropic muscarinic receptors [2,5] and ionotropic nicotinic
receptors [3,6]. The brain expresses five different types of
muscarinic receptors (M1–M5). The nicotinic receptors, which
are formed by five identical or homologous subunits, are generated
from twelve different subunits (nine a-subunits and three b-
subunits) [3]. The various pentameric nAChR subunit combina-
tions have different pharmacological and kinetic properties, and
are widely distributed in the brain. Similar complexity is observed
for the different G-coupled muscarinic receptors. Knowledge of
the interplay between different receptors is not fully understood,
and because of this complexity, defining the actual contribution of
brain ACh to specific behaviors has been challenging.
There have been several attempts to generate animal models of
cholinergic dysfunction by elimination of cholinergic neurons
using electrolytic or excitotoxic methods, which are nonselective
and destroy indistinctly both noncholinergic and cholinergic
neurons, as well by the more selective strategy of cholinergic
immunolesion, which preferentially destroy cholinergic neurons
[1]. Although these studies have provided important information
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regarding the cholinergic system, they also have raised a number
of inconsistent results concerning behavioral processes that are
affected by altering cholinergic transmission [1]. The fact that
some of these techniques may not be specific and can eliminate
non-cholinergic neurons or that they may not eliminate all
cholinergic neurons could explain some of the differences. In
addition, other signalling molecules, such as neuropeptides,
growth factors and co-transmitters, can be co-released by
cholinergic neurons, further confounding the interpretation of
neuronal degeneration-induced cholinergic deficiency. Further-
more, neuronal death causes inflammation which can also
complicate interpretation of the experiments [7–9]. Therefore it
is important to develop alternative, more consistent and targeted
approaches to complement these previous studies and to
investigate specific roles of ACh in brain functions.
Using genetics to generate mouse models of cholinergic
deficiency is equally challenging. ChAT KO mice die shortly
after birth and adult heterozygous ChAT KO mice exhibit
compensatory increases in choline uptake and show no behavioral
phenotype [10,11]. We have recently generated novel mouse lines
of cholinergic deficiency by targeting the vesicular acetylcholine
transporter (VAChT knockdown - VAChT KD and VAChT
knockout - VAChT del/del). VAChT is essential for ACh release as
mice null for VAChT expression do not survive [12]. In contrast,
mice with reduction of VAChT expression by 40% (VAChT
KDHET) and 70% (VAChT KDHOM) are viable [13]. Analysis of
ACh release in VAChT KD mice indicate that decreased
expression of VAChT perturbs storage of ACh in vesicles. During
stimulation, impaired ACh storage becomes more pronounced
leading to significant decrease in ACh release [13,14]. VAChT
KDHOM mice are myasthenic and present social and object
recognition memory deficits [13] and cardiac dysfunction [15],
indicating that perturbation of ACh storage affects several
physiological functions [12,13,15–17]. All these phenotypes can
be rescued by inhibition of cholinesterase, indicating that they are
the result of decreased ACh release due to the exocytosis of
partially-filled synaptic vesicles and are not the result of
developmental changes [13–15].
The organization of the VAChT gene locus is complex. The
entire VAChT open reading frame is encoded by one single exon
that is contained inside the first intron of the ChAT gene [18].
This nested gene structure is frequently named cholinergic gene
locus (CGL). Control of expression of VAChT and ChAT is
poorly understood, and distinct cholinergic neurons show different
requirements for regulatory regions within the cholinergic gene
locus [19–22]. To further investigate the roles of the cholinergic
system we have developed novel strains of VAChT targeted-mice.
Our strategy was to generate a VAChT allele that is flanked by
loxP sequences and carries a TK-Neo resistance cassette
approximately 1.5kb downstream from the VAChT stop codon,
in a ChAT intronic region. We show that interrupting the intron
between ChAT exons N and M with a TK-Neo cassette maintains
VAChT expression in the somatomotor subset of cholinergic
neurons relatively intact, but causes a pronounced decrease in
VAChT expression in other groups of cholinergic neurons in the
CNS. As a consequence, these mice present preserved neuromus-
cular function, but altered brain cholinergic activity. We show that
these new mutant mice are hyperactive when exposed to a new
environment. Interestingly, hyperactivity is a behaviour trait found
in several diseases such as Alzheimer’s disease [23–25], schizo-
phrenia [26,27] and Attention-deficit hyperactivity disorder
[28,29]. Genetic removal of the TK-Neo resistance cassette
rescues VAChT expression and the hyperactivity phenotype.
These results suggest that release of ACh is normally required to
‘‘turn down’’ neuronal circuits controlling locomotion.
Results
Generation of VAChT-deficient mice
We generated a new VAChT targeted mouse line by inserting a
lox-P flanked TK-Neo cassette in the 39 region of the VAChT
gene, in the intron between exons N and M of the ChAT gene,
and a third lox-P sequence 260 bp upstream from the VAChT
translational initiation codon (Figure 1). Successful recombination
of the mutated VAChT allele was confirmed by Southern-blot and
PCR analyses (Fig. 1C and 1D).
We initially characterized this novel mouse line by evaluating
VAChT expression expecting that the new location chosen for the
insertion of the TK-Neo cassette would not alter VAChT gene
expression. However, we found that VAChTFloxNeo/FloxNeo mice
showed a large decrease in VAChT expression in the striatum (76%
decrease in VAChT mRNA- Figure 2A), but VAChT expression in
the spinal cord was decreased only by 46% (Figure 2B). We have
found in previous experiments that decreased expression of VAChT
up to 50% in the spinal cord does not alter neuromuscular function
[12,13]. As the VAChTFloxNeo allele showed much pronounced
decrease of VAChT expression in the brain compared to the spinal
cord, it offered the chance to knock-down VAChT expression in the
brain, but preserve peripheral cholinergic function. To examine this
possibility, we crossed VAChTFloxNeo/FloxNeo mice to heterozygous
VAChT-null mice in order to generated VAChTFloxNeo/del mice
anticipating that this novel mouse line might present even more
significant knockdown of VAChT in the brain, but relatively
preserved peripheral function. Genotyping of these mice was
obtained by PCR (Fig. 1E).
We examined VAChT expression in VAChTFloxNeo/del mice
compared to VAChTwt/wt mice. The levels of mRNA for VAChT
were decreased in the striatum of VAChTFloxNeo/del mice even
further (89% decrease - Fig. 2C). Similarly to VAChTFloxNeo/FloxNeo
mice, VAChT expression in the spinal cord of VAChTFloxNeo/del
mice was relatively preserved (57% decrease, Figure 2D). Confirm-
ing results obtained previously, levels of mRNA for VAChTwt/del
mice decreased 50% when compared to VAChTwt/wt mice
(Figure 2C and [12]). We also examined other components of
cholinergic nerve terminals that can impact cholinergic tone. Of
significant interest both VAChTFloxNeo/del and VAChTwt/del
presented an increase in ChAT mRNA expression in the spinal
cord, but not in the striatum (Fig. 2C and 2D) and this was
compatible with previous findings for the del allele [12]. This
increase in ChAT expression is likely related to the removal of the
VAChT gene with a decrease in the distance between two ChAT
promoters (see Fig. 1). In contrast, ChAT mRNA expression was
not changed in VAChTFloxNeo/FloxNeo mice (Fig, 2A and 2B). Also,
CHT1 and AChase mRNA expression were not changed in any of
the VAChT mutants in either the striatum or spinal cord (Fig. 2A–
D).
To investigate the expression of VAChT in distinct brain
regions we used immunofluorescence. In brain sections VAChT
expression was drastically reduced in the striatum, cortex and
hippocampus of VAChTFloxNeo/del and VAChTFloxNeo/FloxNeo
mice compared to VAChTwt/del or VAChTwt/wt mice (Fig. 3
and 4). In contrast CHT1 labelling was preserved. We also
examined expression of VAChT in the facial motor nuclei (Fig. 4).
Staining in the cell bodies was similar in all genotypes, although
both VAChTFloxNeo/del and VAChTFloxNeo/FloxNeo mice had a
decreased labelling in the punctated fluorescence for nerve
terminals that contact these neurons. To further investigate if
Novel Hypocholinergic Mouse Lines
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indeed VAChT expression was reduced in the brain, we used
immunoblot analysis of striatum tissues. A decrease of 75 to 85%
in the expression of VAChT in the striatum of VAChT mutants
was observed (supplementary Fig. S1).
To further explore VAChT expression in the periphery we
stained VAChT in the NMJ of diaphragm. In contrast to the
decreased VAChT expression in distinct brain regions, we found
negligible differences for VAChT expression in nerve-endings at
the diaphragm of VAChTFloxNeo/del and VAChTFloxNeo/FloxNeo
mice when compared to the two control genotypes (Fig. 5A).
Furthermore, analysis of nicotinic ACh receptor labelling using
fluorescent bungarotoxin suggested normal nAChR distribution
(Fig. 5A).
To test if neuromuscular transmission was preserved in
VAChTFloxNeo/del and VAChTFloxNeo/FloxNeo mice we recorded
from the NMJ of the diaphragm. Both the amplitude and the
frequency of miniature end-plate potentials (MEPPs) were increased
for VAChTFloxNeo/del, VAChTFloxNeo/FloxNeo and VAChTwt/del
mice when compared to VAChTwt/wt (Fig. 5B and C). These results
are compatible with our previous observations that close to 50%
reduction of VAChT at neuromuscular junctions affects quantal
release of ACh only mildly [13]. These results suggest that quantal
release in the two mutant mice with decreased expression of
VAChT in the brain was well preserved at the NMJ.
To examine whether VAChTFloxNeo/del and VAChTFloxNeo/FloxNeo
mice had preserved muscular function we performed a series of
Figure 1. Schematic Drawing of the Cholinergic Gene Locus and Generation of VAChT Deficient Mice. a) Boxes represent the different
exons of ChAT or VAChT. The position of the initiation codon (ATG) for VAChT and ChAT and the stop codon (Stop) of VAChT are indicated. Potential
transcription initiation sites are indicated for VAChT (green arrowheads) and ChAT (orange arrowheads). Note that the VAChT gene is within the first
intron of ChAT. b) Different VAChT alleles generated. P1, P2, P3 and P4 indicate the primers used for PCR genotyping and the fragment sizes generated.
LoxP sequence, some restriction enzymatic sites and probe annealing are represented. c) Southern blot analysis of WT (lane 1), VAChTFloxNeo/FloxNeo(lane
2), VAChTWT/FloxNeo (lane 3), VAChTWT/Del(lane 4) and VAChTFloxNeo/Del(lane 5). d) PCR analysis of VAChTWT/FloxNeo (lanes 1 and 4), VAChTWT/WT (lane 2), and
VAChTFloxNeo/FloxNeo (lanes 3 and 5). e) PCR analysis of VAChT WT/del mice (lane 1), VAChT FloxNeo/Del (lane 2), and VAChT WT/FloxNeo mice (lane 3). f) PCR
analysis of VAChT Flox/Flox mice (lane1), VAChT WTWT mice (lane2 and 4), and VAChT WT/Flox (lane 3 and 5).
doi:10.1371/journal.pone.0017611.g001
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neuromuscular tests. These mutant mice showed no difference in grip-
force andwire-hang tasks suggesting preserved neuromuscular function
(Fig. 6A–D). Moreover, because previous observations showed that
VAChT KDHOM mice had gait problems [13], we also tested if
VAChTFloxNeo/del, VAChTFloxNeo/FloxNeo and VAChTwt/del mice
presented any gait abnormality. In agreement with the lack of
neuromuscular phenotype, we found no gait deficiency in these mutant
mice (Fig. 6 E–F). These results indicate that VAChTFloxNeo/del and
VAChTFloxNeo/FloxNeo mice, unlike VAChT-KDHOM mice, do not
present a neuromuscular phenotype.
We have previously demonstrated that decreased VAChT
expression leads to proportional increase in the amount of total
ACh in the brains of mutant mice, as ACh that is not released
accumulates in nerve terminals [12,13]. Because we did not detect any
alteration in either ChAT or CHT1 in the striatum, we measured the
amount of ACh in the brains of mutant mice as an indirect assessment
of ACh output. We determined the ACh content in the striatum of
VAChTFloxNeo/del mice (the line with largest decrease in VAChT
expression) and VAChTwt/del mice. VAChTFloxNeo/del mice presented
several-fold more ACh in the striatum than wild-type controls,
whereas the increase in VAChTwt/del mice was around two-fold
(Fig. 7). These data show a gene-dosage effect in the ACh content in
these VAChT mutant mice and corroborate the mRNA and protein
findings that the decrease in VAChT expression is more accentuated
in VAChTFloxNeo/del when compared to VAChTWT/del mice.
VAChTFloxNeo/del and VAChTFloxNeo/FloxNeo mice are
hyperactive
As these new VAChT mutant mice have preserved peripheral
function, they became candidates to explore phenotypes that were
previously difficult to study using VAChT KDHOM mice due to
their neuromuscular deficiency. To start assessing the consequences
of decreased VAChT expression for central functions we examined
locomotor activity in the open field, which has been shown to be
altered by antagonists of muscarinic receptors as well as by genetic
elimination of some nicotinic and muscarinic receptors [29–37].
Figure 8 indicates that VAChTFloxNeo/del mice showed increased
locomotion throughout the 2 hour monitoring period when
compared to wild-type controls (Kruskal-Wallis test show difference
between the genotypes (H(3) = 31.680, p,0.001). The average total
distance traveled by VAChTFloxNeo/del mice in 2 h was 2.1-fold
higher than that of WT controls. An intermediate increase (1.4-fold)
in locomotor activity was observed in VAChTFloxNeo/FloxNeo mice
when compared to wild-type controls (Fig. 8A and B). Activity levels
of VAChTwt/del mice showed a tendency to increase however it did
not meet statistical significance, similar to previously reported
observations [12]. These results suggest that decreased VAChT
expression to the levels found in VAChTFloxNeo/del mice causes
abnormal motor activity. In addition, vertical exploration in the
open field was increased in VAChTFloxNeo/del mice as shown by the
number of rearings (Figure 8C and D; Kruskal-Wallis test;
(H(3) = 13.764, p,0.05; post-hoc Dunn reveal a significant higher
rearing number of VAChTFloxNeo/del compared to WT controls).
Lack of habituation does not seem to be the cause of
the hyperactivity as all three mutants showed decreased motor
activity across the 2-hour test session (Figure 8A). Moreover,
VAChTFloxNeo/FloxNeo and VAChTFloxNeo/del mice were retested
after 24 h and 48 h under the same conditions to investigate
intersession habituation and both genotypes showed significant
decrease in locomotor activity in the second and third days
Figure 2. VAChT mRNA expression is changed in VAChT mutant mice. a) VAChT, ChAT, CHT1 and AChase mRNA levels in striatum and b)
spinal cord of WT and VAChTFloxNeo/FloxNeo mice. c) VAChT, ChAT, CHT1 and AChase mRNA levels in striatum and d) spinal cord of VAChTWT/WT,
VAChTFloxNeo/Del and VAChTWT/Del mice. mRNA expression levels were quantified by qPCR using actin to normalize the data. Graphs represent average
of 4–6 different mice. (*) and (**) indicate p,0.01 and p,0.001 respectively.
doi:10.1371/journal.pone.0017611.g002
Novel Hypocholinergic Mouse Lines
PLoS ONE | www.plosone.org 4 March 2011 | Volume 6 | Issue 3 | e17611
Figure 3. VAChT immunorreactivity is altered in VAChT mutant mice. a) Representative optical sections from striatum stained with a VAChT
antibody (green) or b) stained with CHT1 antibody (green). c) Representative optical sections from hippocampus stained with a VAChT antibody or d)
CHT1 antibody (green). Dapi labelling (blue) was used to stain nuclei. Scale bar 50 mm.
doi:10.1371/journal.pone.0017611.g003
Figure 4. VAChT immunorreactivity is altered in VAChT mutant mice. a) Representative optical sections from cortex stained with a VAChT
antibody (green) or b) CHT1 antibody (green). c) Representative optical sections from facial motor nuclei stained with a VAChT antibody or d) CHT1
antibody (green). Dapi labelling (blue) was used to stain nuclei. Scale bar 50 mm.
doi:10.1371/journal.pone.0017611.g004
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[between-sessions habituation in the open field; Figure 9A, two-way
repeated measures ANOVA- main effect of genotype,
F(2, 86) = 15.825, p,0.001, day F(2, 86) = 35.318, p,0.001 and
interaction genotype x day F(4, 86) = 2.505, p,0.05], further
suggesting no impairment in habituation in the novel environ-
ment. It is important to note that even after the third day, both
VAChTFloxNeo/FloxNeo and VAChTFloxNeo/del mice remained
hyperactive when compared to WT (Tukey test respectively
P,0.01 and P,0.001).
We also tested for changes in anxiety level. The time spent in
the center vs. the periphery of the open field was evaluated in the
same open field trials used to quantify locomotor movement. As
shown in Figure 9B VAChTFloxNeo/del mice spent significantly
more time in the center of the open field apparatus (Kruskal-Wallis
test, H(3) = 11.537, p,0.05; post-hoc Dunn’s method, p,0.05)
which could be an indication of reduced anxiety [38]. However,
when we assessed the willingness of VAChT mutant mice to
explore a novel unprotected environment (open arms) of the
elevated plus maze, the time spent in the open arms (Fig. 9C; One
Way Analysis of Variance F(2,58) = 1,603, NS), and the number of
entries in the open arms in the elevated plus maze test (Fig. 9D;
One Way Analysis of Variance F(2,58) = 1,845, NS) were not
significantly affected in VAChTFloxNeo/del mice. These data
indicate that VAChTFloxNeo/del mice do not show consistent
changes in anxiety-related behaviors.
Genetic rescue of VAChT-mutant mice hyperactive
behavior
If decreased VAChT expression causes hyperactivity, it would
be expected that correcting VAChT levels should allow for rescue
of this phenotype. The VAChTFloxNeo allele carries a TK-Neo
cassette 39 from the ORF of VAChT and this is likely the cause of
decreased VAChT expression (Fig. 1). Cre excision of loxP flanked
DNA sequences is a stochastic event [39], we therefore crossed
VAChTFloxNeo/wt mice to distinct Cre mice (see Methods) to
obtain an allele in which the TK-Neo cassette was deleted (Fig. 1B;
VAChTFlox allele). We screened the offspring from this cross by
PCR to identify founder mice carrying only the floxed VAChT
gene, with removal of the TK-Neo cassette. VAChT floxed
founders (VAChTFlox) were crossed to C57BL/6J mice to confirm
germ-line transmission and the progeny obtained were inter-
crossed to obtain VAChTFlox/Flox mice and WT controls (PCR in
Fig. 1F).
We investigated VAChT expression at the mRNA and protein
levels and found that VAChTFlox/Flox mice have essentially the
same level of expression for this transporter as VAChTwt/wt mice
in the striatum, cortex, spinal cord and hippocampus (Fig. 10).
Moreover, ChAT and CHT1 expression were not changed in
VAChTFlox/Flox mice (Fig. 10). Accordingly VAChTFlox/Flox mice
showed no deficits in neuromuscular function in the grip-force
(Fig. 11A) or wire-hang (not shown). Measures of anxiety in the
elevated plus maze were identical to measures of WT controls
(Fig. 11B and C). When we tested VAChTFlox/Flox mice in the
open-field we also found that locomotor activity was identical to
that of VAChTwt/wt mice and no habituation deficits were
observed (Fig. 11D–F). These results strongly suggest the recovery
of VAChT expression by removal of the TK-Neo cassette rescued
the hyperactivity phenotype of VAChTFloxNeo.
Discussion
The VAChTFloxNeo allele shows differential regulation of
VAChT expression
The present experiments explore some of the remarkable
features of the cholinergic gene locus to target VAChT and
generate mice with decreased cholinergic function. We show that
interference with the VAChT-ChAT locus, by insertion of a TK-
Neo cassette in the intron between ChAT exons N and M,
differentially affected the expression of VAChT in the brain and
the spinal cord. Owing to the relative preservation of cholinergic
function in the spinal cord and NMJ, we were able to show that
one of the consequences of reduction of VAChT expression in the
forebrain, and consequent reduction of ACh release, is hyperac-
tivity. This phenotype shows a gene-dose effect with lesser
expression of VAChT causing a more pronounced hyperactivity.
VAChT has a unique genomic organization; its open reading
frame is encoded within the first intron of the ChAT gene. This
arrangement [18] is conserved in nematode [40,41], Drosophila
[42] and mammals [43]. Transcriptional control of the CGL is
rather complex as multiple promoters and alternative splicing are
used to generate different mRNA species from both VAChT and
ChAT genes [44]. Transgenic mice containing different DNA
segments of the CGL fused to reporter genes have been used to
identify regulatory regions that are important for the expression of
VAChT and ChAT in vivo [19,21,22,42,45–47]. These studies
indicate that multiple regulatory elements are necessary to control
expression in the CGL and suggest that regulation of the CGL is
different in different types of cholinergic neurons. Moreover, this
regulatory strategy seems to be conserved in insects and
vertebrates [22,48]. A core promoter containing regulatory
elements necessary to activate the CGL in cholinergic cells and
to repress its activity in non-neuronal cells is present in the
sequence spanning approximately 4 kb upstream of the R exon
[49,50]. Other regulatory elements have been described in the
genomic region between exon-M and the first ChAT coding exon
[22], however the complete set of regulatory sequences controlling
the CGL remains to be determined. A cholinergic group-specific
transcriptional activator has been identified in Drosophila. Mutant
flies that lack expression of the transcription factor abnormal
chemosensory jump6 (acj6) showed decreased ChAT in primary
olfactory neurons, whereas expression in mechanosensory neurons
was unaffected [48].
Our results give further support to the subset-specific regulation
of the CGL. Because the TK-Neo cassette used to generate the
VAChTFloxNeo allele was introduced 450 bp upstream from the
beginning of M-exon, it is reasonable to suggest that its presence
interfered with the function of additional regulatory elements. As
sensorymotor cholinergic neurons rely mainly on the core
promoter [21,22], VAChT expression in these neurons may be
relatively preserved while all the other groups of cholinergic
neurons in the brain have pronounced decrease in VAChT
Figure 5. NMJ morphology and transmission in VAChT mutant mice. a) Diaphragms were immunolabelled with VAChT antibody (green) and
a-bungarotoxin (red) to label nicotinic receptors. Right columns show overlay pictures. Dapi (blue) was used to stain nuclei. Images are representative
of 3 independent experiments. WT control mice (a.1–3), VAChTFloxNeo/FloxNeo mice (a.4–6), WT control mice (a.7–9), VAChTWT/Del mice (a.10–12), and
VAChTFloxNeo/Del mice (a.13–15). No alterations were observed between the genotypes. Scale bar 50mm. b) Quantal size of the four genotypes
quantified by plotting the cumulative frequency of MEPP amplitudes. WT control (black line), VAChTWT/Del mice (red line), VAChTFloxNeo/FloxNeo mice
(blue line) and VAChTFloxNeo/Del mice (green line). c) Frequency of MEPPs at synapses for the four genotypes. (*) indicates statistically significant
difference from control wild-type mice (two-way ANOVA followed by Bonferroni post hoc; F(2,14) = 21,98, p,0.005).
doi:10.1371/journal.pone.0017611.g005
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expression. Interestingly, ChAT expression was not altered in the
VAChTFloxNeo allele. This might suggest that VAChT and ChAT
rely on different regulatory elements. In contrast, mice that present
the VAChTdel allele showed an increased expression of ChAT in
the spinal cord but not in the striatum. These results agree with
our previous experiments showing increased ChAT expression in
the spinal cord of VAChTdel mice [12]; see also Fig. 2 and 3). This
occurs likely due to the proximity of the M-promoter of ChAT to
VAChT promoters after excision of the intervening DNA
sequences flanked by loxP (see Fig. 1). Our experiments suggest
that whereas ChAT expression in the spinal cord may be regulated
by elements that were modified by the del allele, the missing
genomic fragment does not seem to be necessary for regulation of
ChAT expression in the striatum (Fig. 2C and D). Overall, our
experiments examining VAChT and ChAT expression point to
differential gene regulation between the striatum, and likely other
forebrain regions, and the spinal cord. The significance for this
differential regulation for normal cholinergic physiology is poorly
understood, but likely plays an important role to maintain proper
expression level of these two critical cholinergic genes in these
distinct sets of neurons. Although unlikely, we cannot discard the
possibility that expression of the neomycin resistance protein
(aminoglycoside 39-phosphotransferase) may partially contribute
to the phenotypes observed. The fact that VAChT expression was
rescued by the removal of the TK-Neo cassette shows unequiv-
ocally that the two loxP sequences that flank the VAChT gene do
not alter transcription.
VAChTFloxNeo/del and VAChTFloxNeo/FloxNeo mice are
hyperactive
As decreased VAChT expression leads to proportional decrease
in ACh release in the brain [12,13] the availability of mutant
mouse lines displaying different levels of VAChT expression in the
brain (VAChTWT/del mice: 50% decrease; VAChTFloxNeo/FloxNeo
mice: 75% decrease; VAChTFloxNeo/del mice: 85% decrease)
provided us with unique tools to evaluate the consequences of
reduced VAChT levels for brain functions. Also, understanding
the consequences of decreased VAChT expression is made easier
now by the new mouse lines that do not show confounding
peripheral phenotypes.
Because ACh is known to play a major role in the regulation of
locomotor control [51], we used these mutants to investigate the
role of VAChT in locomotor activity. We found that up to 50%
decrease in VAChT expression in the brain does not change
locomotor activity in mice, similar to previous experiments with
VAChT KDHET mice and VAChTwt/del mice. However, our data
show clearly that a more pronounced decrease in VAChT
expression causes hyperactivity in a new environment. These
results suggest that release of ACh is normally required to regulate
neuronal circuits controlling locomotion.
Injection of muscarinic antagonists in distinct brain regions
cause pronounced augmentation in locomotor activity levels
[32,33,35] and a hyperactivity phenotype was observed in mouse
strains lacking M1 and M4 muscarinic receptors [30,31,52] as well
as mouse strains null for the nicotinic b2 receptor [29,36,37].
Paradoxically, systemic injections of nicotinic agonists can cause
an increase in locomotor activity [53–56]. However, this effect
should be considered with caution, as the hyperactivity most
probably results from desensitization of specific types of nicotinic
receptors due to prolonged activation. Therefore, ACh may
regulate locomotor circuitry in multiple and redundant ways. Our
data provide additional support to the notion that insults that
cause cholinergic presynaptic deficiency can also increase activity.
Locomotor hyperactivity is a symptom present in many disorders
including Attention Deficit Hyperactivity Disorder (ADHD),
schizophrenia, Alzheimer’s diseases and some forms of autism [4].
Interestingly, all these disorders have in common some degree of
cholinergic deficit. VAChTFloxNeo/del and VAChTFloxNeo/FloxNeo
mice are novel complementary models to understand the specific
consequences of decreased cholinergic activity in the brain and
should be useful to further investigate the role of ACh in distinct
brain functions. Importantly, as VAChTFlox/Flox mice have
preserved VAChT expression and do not show any phenotype,
they can be used in the future to generate novel lines with
suppression of ACh release in specific brain regions. These
conditional mutants will be valuable to investigate the role of
specific groups of cholinergic neurons in distinct brain functions.
Materials and Methods
Ethics Statement
The experimental procedures in this study were conducted in
compliance with the Canadian Council of Animal Care (CCAC)
Figure 6. Neuromuscular function in VAChT mutant mice. a) Time spent hanging upside down from a wire netting for WT and VAChTFloxNeo/FloxNeo
mice. No significant difference was observed [T(33) = 295, P = 0.728]. b) Wire Hang for WT, VAChT
WT/Del and VAChTFloxNeo/Del mice. No significant difference was
observed [Kruskal-Wallis, H(2) = 2.604, P = 0.272]. c) Grip force measured for WT and VAChT
FloxNeo/FloxNeo mice. There is no significant difference between the two
genotypes [T(21) = 125, P = 0.689]. d) Maximal force expressed in gram. No difference was observed between WT, VAChT
WT/Del and VAChTFloxNeo/Del mice [One
way ANOVA, F(2) = 0.600, P = 0. 507]. e) Gait analysis for WT, VAChT
FloxNeo/FloxNeo mice. No significant difference between genotypes was revealed [Student test,
t(13) = 0.263 P = 0. 797] f) Gait analysis for WT, VAChT
WT/Del and VAChTFloxNeo/Del. No significant difference between genotypes was observed [One way ANOVA,
F(2) = 0.699, P = 0. 559].
doi:10.1371/journal.pone.0017611.g006
Figure 7. Acetylcholine content in the striatum VAChT mutant
mice. Striatal tissue ACh levels for WT, VAChTWT/Del and VAChTFloxNeo/Del
mice were assayed by chemiluminescent detection. Data represent 4–9
experiments (mean 6 SEM). (One-way Anova with Bonferroni post hoc,
F(2,14) = 21,98, (*)p,0. 05* for wild-type controls.
doi:10.1371/journal.pone.0017611.g007
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guidelines for the care and use of animals. The protocol was
approved by the University of Western Ontario Institutional
Animal Care and Use Committee (protocol # 2008-089). All
efforts were made to minimize the suffering of animals.
Generation of VAChT mutant mice
Construction of the gene-targeting vector was described
previously [12]. In short, one LoxP sequence was placed 260 bp
upstream from the VAChT translational initiation codon, and a
second LoxP was added approximately 1.5 kb downstream from
the stop codon. The Neomicin-resistance gene (TK-Neo cassette)
was inserted immediately after the second LoxP and was followed
by a third LoxP (Figure 1). The linearized targeting vector was
electroporated into J1 embryonic stem cells derived from 129/
terSv mice, and selected embryonic stem cell clones harbouring
homologous recombination (determined by PCR and Southern
blotting (not shown) were injected into C57BL/6J blastocysts to
produce chimeric mice. Germ line transmission was achieved, and
mice were bred to C57BL/6J mice to produce heterozygous
mutant mice (VAChTWT/FloxNeo). Heterozygous mice were
intercrossed to generate the homozygous (VAChT FloxNeo/FloxNeo)
and wild-type controls (VAChT
WT/WT
) used in these experiments.
VAChTFloxNeo/del and VAChTWT/del mice were generated by
intercrossing VAChTWT/FloxNeo to heterozygous VAChT KO
mice (VAChTwt/del; [12]. Only male mice were used in this study.
Animals were housed in groups of three to four per cage in a
temperature-controlled room with a 12:12 light-dark cycles in
microisolator cages. Food and water were provided ad libitum.
Mouse colonies were maintained at the University of Western
Ontario, Canada, in accordance with Canadian Council of
Animal Care (CCAC) guidelines for the care and use of animals.
Genotyping, Southern blotting
Genotyping by PCR was performed using tail DNA as a
template. The set of three primers used were P1 (5-GAGAG-
TACTTTGCCTGGGAG GA -3), P2 (5- GGCCACAGTAA-
GACCTCCCTTG -3), P3 (5- GCAAAGCTGCTATTGGC-
CGCTG -3) and P4 (5-TCATAGCCCCAAGTGGAG-
Figure 8. VAChT mutant mice are hyperactive. a) Spontaneous horizontal activity during two hours in the open field for WT, VAChTWT/Del,
VAChTFloxNeo/FloxNeo and VAChTFloxNeo/Del mice. b) Total spontaneous horizontal activity during the two hour was increased for VAChTFloxNeo/FloxNeo
and VAChTFloxNeo/Del mice compared to WT/WT. But no difference between WT and VAChTWT/Del was observed. c) Spontaneous vertical activity during
two hours in the open field for WT, VAChTWT/Del, VAChTFloxNeo/FloxNeo and VAChTFloxNeo/Del mice. d) Total number of rearings during the two hour
period. Rearings for VAChTFloxNeo/Del were significantly higher when compared to WT (Kruskal-Wallis test; (H(3) = 13.764, post-hoc Dunn p,0.05).
(*) indicate p,0.01.
doi:10.1371/journal.pone.0017611.g008
Novel Hypocholinergic Mouse Lines
PLoS ONE | www.plosone.org 10 March 2011 | Volume 6 | Issue 3 | e17611
GGAGA-3). For Southern blot analysis, genomic DNA was
digested with the enzymes BamHI and SacI. Digested DNA was
subjected to electrophoresis in a 1.5% agarose gel and transferred
onto a nylon membrane. After UV cross-linking, DNA on the
membrane was hybridized to the NdeI/PmeI VAChT DNA
fragment (see Fig. 1 for the position of the probe fragment).
Detection was done using the Alkphos direct labelling and
detection system kit (GE Healthcare) according to the manufac-
turer’s instructions.
qPCR
For real-time quantitative PCR (qPCR), total RNA was extracted
using the Aurum Total RNA for fatty and fibrous tissue kit from
Biorad. Quantification and quality analysis of RNA in the extracted
samples was done by microfluidic analysis (Agilent Technologies’
Bioanalyzer). First-strand cDNAwas synthesized using the iSCRIPT
cDNA SYNTHESIS KIT from Biorad. cDNA was subsequently
subjected to qPCR on a CFX-96 Real Time System (Bio-Rad) using
the iQ SYBR GREEN SUPERMIX (Bio-Rad). For each experi-
ment, a non-template reaction was used as a negative control. In
addition, the absence of DNA contaminants was assessed in reverse
transcription-negative samples and by melting-curve analysis.
Relative quantification of gene expression was done with the DDCT
method using b-actin gene expression to normalize the data.
Western blotting
Immunoblot analysis was carried out as described previously
[12]. Antibodies used were anti-VAChT (rabbit polyclonal 1:2000,
Synaptic System, Germany), anti-CHT1 (rabbit polyclonal
1:1000, kindly provided by R. Jane Rylett, University of Western
Ontario, London, Canada), anti-CHAT (rabbit polyclonal 1:1000,
Chemicon) and anti-actin (Chemicon, CA). Images were acquired
using the FluorChem Q System from Alpha Innotech and
analysed using the AlphaVie software.
Immunofluorescence analysis of brain slices were performed as
described previously [12]. Images were acquired using an Axiovert
200 M using the ApoTome system or a LEICA SP5 confocal
microscope as previously described [17].
Figure 9. Habituation and anxiety are not changed in VAChT mutant mice. a) Habituation to open field during 3 consecutive days for WT,
VAChTFloxNeo/FloxNeo and VAChTFloxNeo/Del mice. Mice showed no impairment in habituation in the novel environment. Two-way repeated measures
ANOVA- main effect of genotype,F(2, 86) = 15.825, p,0.001, day F(2, 86) = 35.318, p,0.001 and interaction genotype x day F(4, 86) = 2.505, p,0.05]. b)
Time spend in the centre during the 2 hour in the open field for WT, VAChTWT/Del, VAChTFloxNeo/FloxNeo and VAChTFloxNeo/Del mice. VAChTFloxNeo/del
mice spent significant more time in the center of the open field apparatus (Kruskal-Wallis test, H(3) = 11.537, p,0.05; post-hoc Dunn’s method,
p,0.05). c) Time spend in the open arm of elevated plus maze for WT, VAChTFloxNeo/FloxNeo and VAChTFloxNeo/Del mice was not significantly affected.
One Way Analysis of Variance F(2,58) = 1,603, NS). d) Number of entries in the open arm of elevated plus maze for WT, VAChT
FloxNeo/FloxNeo and
VAChTFloxNeo/Del mice was not significantly affected. One Way Analysis of Variance (F(2,58) = 1,845, NS). (*), (**) and (***) indicate p,0.05, p,0.01 and
p,0.001 respectively.
doi:10.1371/journal.pone.0017611.g009
Novel Hypocholinergic Mouse Lines
PLoS ONE | www.plosone.org 11 March 2011 | Volume 6 | Issue 3 | e17611
Novel Hypocholinergic Mouse Lines
PLoS ONE | www.plosone.org 12 March 2011 | Volume 6 | Issue 3 | e17611
Tissue ACh measurements
Brains were dissected rapidly, homogenized in 5% TCA, and
centrifuged (10,0006g for 10 min) at 4uC. Supernatants were
frozen at 280uC until use. For ACh determinations, TCA was
removed with ether, and a chemiluminescent assay was done with
choline oxidase as described previously [44]. The data are
presented as means and standard errors of the means (SEM).
One-way analysis of variance (ANOVA), followed by Bonferroni’s
test, was used to analyze the differences in tissue ACh
concentrations in VAChTFloxNeo/del, VAChTFloxNeo/FloxNeo,
VAChTWT/del and wild-type controls (VAChTWT/WT); a
P,0.05 was considered to be statistically significant.
Electrophysiology
Recordings were performed on isolated hemi-diaphragm nerve-
muscle preparations. Animals were euthanized and the diaphragm
with attached rib bone was rapidly dissected and placed into
Tyrode’s solution containing NaCl (124 mM), KCl (5 mM),
NaHCO3 (26 mM), NaH2PO4 (1.2 mM), MgCl2 (1.3 mM), CaCl2
(2.4 mM), glucose (10 mM). This solution was gassed with a
mixture of 5%CO2/95%O2 and in this condition had a pH of 7.4.
The diaphragm was bisected, and one half was transferred into a
custom recording chamber in which the muscle was held in place
with metal pins that passed through the surrounding tissue and
were inserted into a Sylguard bed. During recording, the muscle
was continuously perfused with gassed Tyrode solution containing
0.0003 mM tetrodotoxin to avoid spontaneous action potentials.
Borosilicate (WPI) microelectrodes were fabricated on a Narashige
PN-30 puller, and had resistances of 5–15 MOhm when filled with
3 M KCl. Fine branches of the motor nerve were visually
identified under 100X magnification and the muscle fiber was
impaled using a fine micromanipulator (WPI). Membrane
potential and synaptic potentials were amplified 10X with an
Axon Instruments Axoclamp 2A, and membrane potential was
monitored throughout the experiment. To digitalize the miniature
endplate potentials (MEPPs), the signal was high-pass filtered at
0.1 Hz to subtract the resting potential and amplified a further
200-1000X using a Cyberamp (Axon Instruments) amplifier. This
signal was fed to a Lab Master A–D conversion board controlled
by Strathclyde Electrophysiology Software (University of Strath-
clyde, Glasgow, Scotland). To measure quantal size, a software
event detector was used to record 25 ms of data on either side of
the MEPP. The threshold of the event detector was set just below
the peak of the noise so as not to miss any small MEPPs. Under
these conditions, approximately 15% of detected ‘‘MEPPs’’ were
false positives and were manually detected and removed. To
measure MEPP frequency, membrane potential was recorded
without selection, and MEPPs were manually identified and
counted.
Grip force and wire-hang
Mice were brought to the testing room and allowed to acclimatize
for 10 minutes before initiating tests. A Grip Strength Meter from
Columbus Instruments (Columbus, OH) was used to measure
forelimb grip strength as an indicator of neuromuscular function as
described previously [12,13]. Briefly, the grip strength meter was
positioned horizontally and mice were held by the tail and lowered
toward the apparatus. Mice were allowed to grasp the smooth,
metal, triangular pull bar (forelimbs only) and were then pulled
backward in the horizontal plane. The force applied to the bar at
the moment the grasp was released was recorded as the peak tension
(kg). The test was repeated 10 consecutive times within the same
session and the highest value from the 10 trials was recorded as the
grip strength for that animal. Mice were not trained prior to testing
and each mouse was tested once (10 trials equal one test session).
For wire-hanging experiments the laterals of a cage top were
covered with tape to prevent the mice to reach the borders [57].
The mouse was gently put on the cage top, which was then briefly
shaken to induce the mouse to grasp the wire in the top. The cage
top was then inverted and suspended approximately 40 cm above
an empty cage. Time spent hanging upside down was determined
with a cut-off time of 60 sec.
Gait analysis
Mice were subjected to gait assessment [58] using a CatWalk
automated gait analysis system (Noldus Information Technology).
The apparatus is made of a 1.3 m long glass plate with dim
fluorescent light beamed into the glass from the side. The reflexion
of the paw in contact to the glass was recorded by a video camera.
Mice were placed in the walkway and allowed free exploration for
1 min before recording the first run. A minimum of 3 correct runs
(the mouse cross the walkway with no interruption or hesitation)
for each mouse was recorded. Runs were analysed using the
Noldus software and only the runs where it was possible to discern
all steps were used for the analysis. We only used the mean stride
length of hind paw as data, stride length is the distance between
two successive prints of the same paw.
Locomotor activity and habituation
Locomotor activity was automatically recorded (AccuScan
Instrument, Inc. Columbus, OH). The open field arena was a
20 cm620 cm platform surrounded by 30 cm high walls. Mice
were acclimated to the testing room for 20 minutes prior to
beginning the test, and had not experienced a cage change for at
least 24 hours. Mice were placed in the center of the apparatus
and allowed to freely explore the arena. Horizontal locomotion
and rearings were recorded and used as measures of locomotion
and exploration, respectively [59]. Locomotor activity was
measured at 5 min intervals and cumulative counts (120 min)
were taken for data analysis as described elsewhere [60]. For the
intersession habituation, mice were exposed for 120 min to the
same open field during 3 consecutive days. Measurements of total
activity were obtained and one-way ANOVA and Tukey’s
Multiple Comparison Test was used to test for statistical
significance. Activity was measured by the Versamax software.
Elevated Plus-maze
Animals were placed in the center of the elevated plus maze
(Med Associate Inc.) and activity was recorded for five minutes
with a webcam connected to a computer. Total amount of time
spent in the open and in the open sections of the maze was
calculated with the Any-maze software (Stoelting Co., USA); an
Figure 10. Genetic rescue of VAChT-mutant mice. a) VAChT, ChAT, and CHT1 mRNA levels were measured by qPCR in the striatum of WT mice
(white bar), VAChTWT/Flox (grey bar) and VAChTFlox/Flox (black bar) mice. b) VAChT, ChAT, CHT1 mRNA levels in the spinal cord of WT mice (white bar),
VAChTWT/Flox (grey bar) and VAChTFlox/Flox (black bar) mice. c) Representative immunoblot of control, VAChTWT/Flox and VAChTFlox/Flox mice in striatum.
d) Quantification of protein levels. Actin immunoreactivity was used to correct for protein loading between experiments. Data are presented as a
percentage of wild-type levels. e) Representative immunoblot of control, VAChTWT/Flox and VAChTFlox/Flox mice in spinal cord. f) Quantification of
protein levels. Actin immunoreactivity was used to correct for protein loading between experiments. Data are presented as a percentage of wild-type
levels.
doi:10.1371/journal.pone.0017611.g010
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animal was considered to be completely within a section of the
maze when its center of gravity was in this section. The result was
expressed as the percentage of time spent in the open arm.
Statistical Analysis
Data were statistically analyzed by a two-tailed Student’s t test
or by two-way or repeated measure ANOVA. If data were not
normal, we used the adequate non-parametric test. The specific
statistical analyses used are noted in the text and legends.
Supporting Information
Figure S1 Protein expression is changed in VAChT
mutant mice. a) Western blot analysis of VAChT in the striatum
of VAChTFloxNeo/FloxNeo mice compared to WT control and b)
quantification of protein levels. c) Western blot analysis of VAChT
in the striatum of VAChTFloxNeo/Del mice, VAChTWT/Del and
VAChTWT/WT. d) quantification of protein levels. Actin immuno-
reactivity was used to correct for protein loading between
experiments. Data are presented as a percentage of wild-type levels.
Graphs represent average of 4–6 different mice. (*) indicates
statistically different from WT/WT control (Student test, p,0.05),
(**) indicates statistically different from VAChTWT/Del (Student test,
p,0.01).
(TIF)
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